Please assess the completion status of the following clinical trial:

Trial Title: Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over the age of 18 year.~* Patients diagnosed with advanced melanoma.~* Patients that are considered candidates for ipilimumab therapy.~* Patients able to understand and willing to sign a written informed consent documents.~* Patients willing to have regular blood draws, one before treatment and four during or after treatment.~Exclusion Criteria:~* Patients under the age of 18.~* Patients with Stage I or II, melanoma who are not candidates for Ipilimumab.~* Patients that have received systemic treatments within four weeks prior to the beginning of treatment.~* Women that are pregnant or nursing.~* Patients taking immunosuppressive medications.~* Patients with active autoimmune disease.~* Patients with known sensitivity to retinoic acid derivatives.~* Patients with aspartate aminotransferase (AST), alanine aminotransferase (ALT), or bilirubin \> 2.5 × ULN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Ipilimumab (Type: ACTIVE_COMPARATOR): Arm A (No VESANOIDTherapy) will receive the standard of care treatment with ipilimumab only, receiving the standard 4 doses of either 3 or 10 mg/kg ipilimumab every 3 weeks.
- VESANOID (Type: EXPERIMENTAL): Arm B (VESANOID Therapy) will receive the standard 4 doses of either 3 or 10 mg/kg ipilimumab every three weeks plus the supplemental treatment of 150 mg/m2 of VESANOID orally for 3 days surrounding each dose of ipilimumab (day -1, day 0, day +1) for a total of 12 days of VESANOID treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).